TY  - JOUR
AU  - Đurasinović, Vladislava T.
AU  - Mihaljević, Biljana
AU  - Šipetić-Grujičić, Sandra B.
AU  - Ignjatović, Svetlana
AU  - Trajković, Goran
AU  - Todorović-Balint, Milena R.
AU  - Antić, Darko
AU  - Bila, Jelena S.
AU  - Anđelić, Bosko M.
AU  - Jelicić, Jelena J.
AU  - Vuković, Vojin M.
AU  - Nikolić, Aleksandra M.
AU  - Klek, Stanislaw
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3236
AB  - Introduction Vitamin D has a role in cellular differentiation, proliferation, apoptosis, and angiogenesis and therefore is studied as a prognostic factor in cancer. The aim of our study was to assess the prevalence and significance of 25(OH)D deficiency in patients with lymphoid malignancies. Methodology Between January 2014 and June 2016 at the Clinic for Hematology, Clinical Center of Serbia, Belgrade, the pretreatment serum level of 25(OH)D was determined in 133 (62 women/71 men, median age 58 (18-84) years) previously untreated patients with lymphoid malignancy using a chemiluminescent immunoassay. From their medical records, we noted the age, clinical stage, Eastern Cooperative Oncology Group Performance Scale (ECOG PS), nutritional status using the Nutritional Risk Score 2002 (NRS2002), the time of year, comorbidity index, progression, and progression-free survival (PFS) for a median of 20 (1-32) months. The optimal cutoff point for prediction of outcome was determined using the Maximally Selected Rank Statistics. Results There were 37 (27.8%) patients with the severe 25(OH)D deficiency  lt = 25 nmol/l, 80 (60.2%) with 25(OH)D deficiency 25-50 nmol/l, and 16 (12%) with 25(OH)D insufficiency 50-75 nmol/l. None of the patients had the desired normal level. There were significant differences between groups in regard to ECOG PS, NRS2002, type of lymphoma, and progression. The severely 25(OH)D-deficient patients had a shorter mean time until progression (P = 0.018). Cox regression analysis showed that 25(OH)D  lt  19.6 nmol/l remained the only significant parameter for PFS (HR = 2.921; 95% CI 1.307-6.529). Conclusion The prevalence of 25(OH)D deficiency in the analyzed group of patients with lymphoid malignancies is high and greater in malnourished individuals. Patients with pretreatment serum 25(OH)D  lt  19.6 nmol/l had a significantly shorter PFS.
PB  - Springer, New York
T2  - Synthetic Communications
T1  - 25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?
VL  - 26
IS  - 8
SP  - 2825
EP  - 2832
DO  - 10.1007/s00520-018-4101-9
ER  - 

@article{
author = "Đurasinović, Vladislava T. and Mihaljević, Biljana and Šipetić-Grujičić, Sandra B. and Ignjatović, Svetlana and Trajković, Goran and Todorović-Balint, Milena R. and Antić, Darko and Bila, Jelena S. and Anđelić, Bosko M. and Jelicić, Jelena J. and Vuković, Vojin M. and Nikolić, Aleksandra M. and Klek, Stanislaw",
year = "2018",
abstract = "Introduction Vitamin D has a role in cellular differentiation, proliferation, apoptosis, and angiogenesis and therefore is studied as a prognostic factor in cancer. The aim of our study was to assess the prevalence and significance of 25(OH)D deficiency in patients with lymphoid malignancies. Methodology Between January 2014 and June 2016 at the Clinic for Hematology, Clinical Center of Serbia, Belgrade, the pretreatment serum level of 25(OH)D was determined in 133 (62 women/71 men, median age 58 (18-84) years) previously untreated patients with lymphoid malignancy using a chemiluminescent immunoassay. From their medical records, we noted the age, clinical stage, Eastern Cooperative Oncology Group Performance Scale (ECOG PS), nutritional status using the Nutritional Risk Score 2002 (NRS2002), the time of year, comorbidity index, progression, and progression-free survival (PFS) for a median of 20 (1-32) months. The optimal cutoff point for prediction of outcome was determined using the Maximally Selected Rank Statistics. Results There were 37 (27.8%) patients with the severe 25(OH)D deficiency  lt = 25 nmol/l, 80 (60.2%) with 25(OH)D deficiency 25-50 nmol/l, and 16 (12%) with 25(OH)D insufficiency 50-75 nmol/l. None of the patients had the desired normal level. There were significant differences between groups in regard to ECOG PS, NRS2002, type of lymphoma, and progression. The severely 25(OH)D-deficient patients had a shorter mean time until progression (P = 0.018). Cox regression analysis showed that 25(OH)D  lt  19.6 nmol/l remained the only significant parameter for PFS (HR = 2.921; 95% CI 1.307-6.529). Conclusion The prevalence of 25(OH)D deficiency in the analyzed group of patients with lymphoid malignancies is high and greater in malnourished individuals. Patients with pretreatment serum 25(OH)D  lt  19.6 nmol/l had a significantly shorter PFS.",
publisher = "Springer, New York",
journal = "Synthetic Communications",
title = "25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?",
volume = "26",
number = "8",
pages = "2825-2832",
doi = "10.1007/s00520-018-4101-9"
}

Đurasinović, V. T., Mihaljević, B., Šipetić-Grujičić, S. B., Ignjatović, S., Trajković, G., Todorović-Balint, M. R., Antić, D., Bila, J. S., Anđelić, B. M., Jelicić, J. J., Vuković, V. M., Nikolić, A. M.,& Klek, S.. (2018). 25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?. in Synthetic Communications
Springer, New York., 26(8), 2825-2832.
https://doi.org/10.1007/s00520-018-4101-9

Đurasinović VT, Mihaljević B, Šipetić-Grujičić SB, Ignjatović S, Trajković G, Todorović-Balint MR, Antić D, Bila JS, Anđelić BM, Jelicić JJ, Vuković VM, Nikolić AM, Klek S. 25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?. in Synthetic Communications. 2018;26(8):2825-2832.
doi:10.1007/s00520-018-4101-9 .

Đurasinović, Vladislava T., Mihaljević, Biljana, Šipetić-Grujičić, Sandra B., Ignjatović, Svetlana, Trajković, Goran, Todorović-Balint, Milena R., Antić, Darko, Bila, Jelena S., Anđelić, Bosko M., Jelicić, Jelena J., Vuković, Vojin M., Nikolić, Aleksandra M., Klek, Stanislaw, "25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?" in Synthetic Communications, 26, no. 8 (2018):2825-2832,
https://doi.org/10.1007/s00520-018-4101-9 . .

TY  - JOUR
AU  - Đorđević, Vladimir
AU  - Buha, Aleksandra
AU  - Radojković, Željko
AU  - Zarić, Nemanja
AU  - Ostojić, Slavenko
AU  - Lekić, Nebojša
AU  - Ninić, Aleksandar
AU  - Ćulafić, Milica
AU  - Mihaljević, Biljana
AU  - Antić, Darko
AU  - Vuković, Vojin
AU  - Kerkez, Mirko
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2556
AB  - Following solid organ transplantation, the patient's management includes the provision of immunosuppressive therapy to the recipient. All kidney transplant recipients require lifelong immunosuppression. Regardless the improving survival following solid organ transplantation, post-transplant complications such as the development of malignancy due to immunosuppression remain to be an issue. One of the most common malignancies encountered in the post-solid organ transplant is lymphoproliferative disorder likely developed as a consequence of immunosuppression. We report a case of plasma cell type lymphoma in the ileocecal region of a 45-year-old male kidney transplant patient who was on a tacrolimus-based regimen for ten years. Although literature data indicate differently localized lymphoma as an adverse reaction to the long term use of tacrolimus, to our knowledge, this is the first described case of lymphoma in the ileocecal region. Serious adverse drug reactions and potential toxicity of tacrolimus emphasize the importance of finding the optimal balance between effective drug concentration and the risk associated with its use.
AB  - Nakon transplantacije organa, pacijenti primaoci organa se stavljaju na režim imunosupresivne terapije, a u primalaca bubrega ta terapija je doživotna. Bez obzira na poboljšanje preživljavanja nakon transplantacije organa, brojne su komplikacije koje se mogu javiti nakon transplantacije, a razvoj maligniteta usled imunosupresije nastavlja da bude značajan problem. Jedan od najčešćih tipova maligniteta koji se sreće kod ovakvih pacijenata je limfoproliferativni poremećaj koji se verovatno razvija kao posledica pomenute imunosupresije. Opisan je slučaj limfoma u ileocekalnoj regiji u 45-godišnjeg muškarca sa transplantiranim bubregom, koji je bio na imunosupresivnoj terapiji zasnovanoj na takrolimusu, tokom 10 godina. Literaturni podaci ukazuju na drugačiju lokalizaciju limfoma kao neželjene reakcije nakon dugoročnog korišćenja takrolimusa, pa je prema našim saznanjima, ovo jedinstven slučaj razvoja limfoma u ileocekalnoj regiji. Ozbiljne neželjene reakcije i toksični potencijal takrolimusa naglašavaju značaj pronalaženja optimalnog balansa između efektivne koncentracije leka i rizika vezanih za njegovu upotrebu.
PB  - Most Art doo, Beograd
T2  - MD - Medical data
T1  - Development of Hodgkin lymphoma in the ileocecal region in kidney transplant patient on long term immunosuppressive therapy: A case report
T1  - Razvoj Hodžkinovog limfoma u ileocekalnoj regiji pacijenta sa transplantiranim bubregom na dugoročnoj imunosupresivnoj terapiji - prikaz slučaja
VL  - 8
IS  - 4
SP  - 265
EP  - 269
UR  - https://hdl.handle.net/21.15107/rcub_farfar_2556
ER  - 

@article{
author = "Đorđević, Vladimir and Buha, Aleksandra and Radojković, Željko and Zarić, Nemanja and Ostojić, Slavenko and Lekić, Nebojša and Ninić, Aleksandar and Ćulafić, Milica and Mihaljević, Biljana and Antić, Darko and Vuković, Vojin and Kerkez, Mirko",
year = "2016",
abstract = "Following solid organ transplantation, the patient's management includes the provision of immunosuppressive therapy to the recipient. All kidney transplant recipients require lifelong immunosuppression. Regardless the improving survival following solid organ transplantation, post-transplant complications such as the development of malignancy due to immunosuppression remain to be an issue. One of the most common malignancies encountered in the post-solid organ transplant is lymphoproliferative disorder likely developed as a consequence of immunosuppression. We report a case of plasma cell type lymphoma in the ileocecal region of a 45-year-old male kidney transplant patient who was on a tacrolimus-based regimen for ten years. Although literature data indicate differently localized lymphoma as an adverse reaction to the long term use of tacrolimus, to our knowledge, this is the first described case of lymphoma in the ileocecal region. Serious adverse drug reactions and potential toxicity of tacrolimus emphasize the importance of finding the optimal balance between effective drug concentration and the risk associated with its use., Nakon transplantacije organa, pacijenti primaoci organa se stavljaju na režim imunosupresivne terapije, a u primalaca bubrega ta terapija je doživotna. Bez obzira na poboljšanje preživljavanja nakon transplantacije organa, brojne su komplikacije koje se mogu javiti nakon transplantacije, a razvoj maligniteta usled imunosupresije nastavlja da bude značajan problem. Jedan od najčešćih tipova maligniteta koji se sreće kod ovakvih pacijenata je limfoproliferativni poremećaj koji se verovatno razvija kao posledica pomenute imunosupresije. Opisan je slučaj limfoma u ileocekalnoj regiji u 45-godišnjeg muškarca sa transplantiranim bubregom, koji je bio na imunosupresivnoj terapiji zasnovanoj na takrolimusu, tokom 10 godina. Literaturni podaci ukazuju na drugačiju lokalizaciju limfoma kao neželjene reakcije nakon dugoročnog korišćenja takrolimusa, pa je prema našim saznanjima, ovo jedinstven slučaj razvoja limfoma u ileocekalnoj regiji. Ozbiljne neželjene reakcije i toksični potencijal takrolimusa naglašavaju značaj pronalaženja optimalnog balansa između efektivne koncentracije leka i rizika vezanih za njegovu upotrebu.",
publisher = "Most Art doo, Beograd",
journal = "MD - Medical data",
title = "Development of Hodgkin lymphoma in the ileocecal region in kidney transplant patient on long term immunosuppressive therapy: A case report, Razvoj Hodžkinovog limfoma u ileocekalnoj regiji pacijenta sa transplantiranim bubregom na dugoročnoj imunosupresivnoj terapiji - prikaz slučaja",
volume = "8",
number = "4",
pages = "265-269",
url = "https://hdl.handle.net/21.15107/rcub_farfar_2556"
}

Đorđević, V., Buha, A., Radojković, Ž., Zarić, N., Ostojić, S., Lekić, N., Ninić, A., Ćulafić, M., Mihaljević, B., Antić, D., Vuković, V.,& Kerkez, M.. (2016). Development of Hodgkin lymphoma in the ileocecal region in kidney transplant patient on long term immunosuppressive therapy: A case report. in MD - Medical data
Most Art doo, Beograd., 8(4), 265-269.
https://hdl.handle.net/21.15107/rcub_farfar_2556

Đorđević V, Buha A, Radojković Ž, Zarić N, Ostojić S, Lekić N, Ninić A, Ćulafić M, Mihaljević B, Antić D, Vuković V, Kerkez M. Development of Hodgkin lymphoma in the ileocecal region in kidney transplant patient on long term immunosuppressive therapy: A case report. in MD - Medical data. 2016;8(4):265-269.
https://hdl.handle.net/21.15107/rcub_farfar_2556 .

Đorđević, Vladimir, Buha, Aleksandra, Radojković, Željko, Zarić, Nemanja, Ostojić, Slavenko, Lekić, Nebojša, Ninić, Aleksandar, Ćulafić, Milica, Mihaljević, Biljana, Antić, Darko, Vuković, Vojin, Kerkez, Mirko, "Development of Hodgkin lymphoma in the ileocecal region in kidney transplant patient on long term immunosuppressive therapy: A case report" in MD - Medical data, 8, no. 4 (2016):265-269,
https://hdl.handle.net/21.15107/rcub_farfar_2556 .

TY  - JOUR
AU  - Mitrović, Mirjana
AU  - Šumarac, Zorica
AU  - Antić, Darko
AU  - Bogdanović, Andrija
AU  - Elezović, Ivo
AU  - Vukosavljević, Dragana
AU  - Ignjatović, Svetlana
AU  - Majkić-Singh, Nada
AU  - Suvajdzić, Nada
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1754
PB  - Academic Press Inc Elsevier Science, San Diego
T2  - Blood Cells Molecules and Diseases
T1  - Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy
VL  - 49
IS  - 1
SP  - 58
EP  - 59
DO  - 10.1016/j.bcmd.2012.03.003
ER  - 

@article{
author = "Mitrović, Mirjana and Šumarac, Zorica and Antić, Darko and Bogdanović, Andrija and Elezović, Ivo and Vukosavljević, Dragana and Ignjatović, Svetlana and Majkić-Singh, Nada and Suvajdzić, Nada",
year = "2012",
publisher = "Academic Press Inc Elsevier Science, San Diego",
journal = "Blood Cells Molecules and Diseases",
title = "Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy",
volume = "49",
number = "1",
pages = "58-59",
doi = "10.1016/j.bcmd.2012.03.003"
}

Mitrović, M., Šumarac, Z., Antić, D., Bogdanović, A., Elezović, I., Vukosavljević, D., Ignjatović, S., Majkić-Singh, N.,& Suvajdzić, N.. (2012). Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy. in Blood Cells Molecules and Diseases
Academic Press Inc Elsevier Science, San Diego., 49(1), 58-59.
https://doi.org/10.1016/j.bcmd.2012.03.003

Mitrović M, Šumarac Z, Antić D, Bogdanović A, Elezović I, Vukosavljević D, Ignjatović S, Majkić-Singh N, Suvajdzić N. Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy. in Blood Cells Molecules and Diseases. 2012;49(1):58-59.
doi:10.1016/j.bcmd.2012.03.003 .

Mitrović, Mirjana, Šumarac, Zorica, Antić, Darko, Bogdanović, Andrija, Elezović, Ivo, Vukosavljević, Dragana, Ignjatović, Svetlana, Majkić-Singh, Nada, Suvajdzić, Nada, "Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy" in Blood Cells Molecules and Diseases, 49, no. 1 (2012):58-59,
https://doi.org/10.1016/j.bcmd.2012.03.003 . .